Evidence map›Paper›PMID 40658158›Full record

ArticleEJNMMI physics2025

Assessment and clinical relevance of pulmonary shunt on

Evelyn Vranken, An De Crop, Victor Nuttens, Ruben Vandenbulcke, Tom Dewaele, Thomas Ryckaert, Jochen Decaestecker, Sofie De Meulder, Pieter De Bondt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Evelyn VrankenAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium. Evelyn.Vranken@azdelta.be.ORCID http://orcid.org/0009-0004-4355-1918
An De CropAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium.
Victor NuttensAZORG, Moorselbaan, 9300, Aalst, Belgium.
Ruben VandenbulckeAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium.
Tom DewaeleAZORG, Moorselbaan, 9300, Aalst, Belgium.
Thomas RyckaertAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium.
Jochen DecaesteckerAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium.
Sofie De MeulderAZ Delta Vzw, Deltalaan 1, 8800, Roeselare, Belgium.
Pieter De BondtAZORG, Moorselbaan, 9300, Aalst, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPrediction of posttreatment lung mean dose (LMD) during liver radioembolization (RE) work-up is essential for risk evaluation of radiation pneumonitis, especially when treating large hepatocellular carcinoma (HCC) where the chance of arteriovenous shunting is not negligible. In case of holmium-166-([ MATERIALS AND

methodsTwenty-nine HCC patients referred for RE were retrospectively evaluated. All work-ups were performed with

resultsIn the 29 patients, average predicted posttreatment LMD was 10.0 Gy (range 0.1-138.9 Gy), four of them revealing predicted LMD > 30 Gy. Based on patient-specific injected

conclusionThis study supports previous reports that

Indexed as

Hepatocellular carcinomaHolmium-166Lung mean doseRadiation pneumonitisRadioembolization

Identifiers

PMID40658158
PMCPMC12259507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.